Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023;15(2):27-52.
doi: 10.1007/s40506-023-00263-w. Epub 2023 Apr 18.

Dengue: Update on Clinically Relevant Therapeutic Strategies and Vaccines

Monica Palanichamy Kala  1 , Ashley L St John  1   2   3   4 , Abhay P S Rathore  4
Affiliations
Review

Dengue: Update on Clinically Relevant Therapeutic Strategies and Vaccines

Monica Palanichamy Kala et al. Curr Treat Options Infect Dis. 2023.

Abstract

Dengue viruses (DENV) continue to circulate worldwide, resulting in a significant burden on human health. There are four antigenically distinct serotypes of DENV, an infection of which could result in a potentially life-threatening disease. Current treatment options are limited and rely on supportive care. Although one dengue vaccine is approved for dengue-immune individuals and has modest efficacy, there is still a need for therapeutics and vaccines that can reduce dengue morbidities and lower the infection burden. There have been recent advances in the development of promising drugs for the treatment of dengue. These include direct antivirals that can reduce virus replication as well as host-targeted drugs for reducing inflammation and/or vascular pathologies. There are also new vaccine candidates that are being evaluated for their safety and efficacy in preventing dengue disease. This review highlights nuances in the current standard-of-care treatment of dengue. We also discuss emerging treatment options, therapeutic drugs, and vaccines that are currently being pursued at various stages of preclinical and clinical development.

Keywords: Dengue fever; Mast cells; Metabolic disorders; Therapeutics; Vaccines; Vascular leakage.

PubMed Disclaimer

Conflict of interest statement

Conflict of InterestDr. Rathore has patents related to dengue therapeutics, PCT/US11426408 and PCT/US11219616. Dr. St. John has patents related to dengue therapeutics, PCT/US11426408 and PCT/US9730921B2. Ms. Monica Palanichamy Kala declares no competing interests.

Figures

Fig. 1
Fig. 1
The clinical management and possible treatment options for dengue disease. Diagram was made using biorender.com
See this image and copyright information in PMC

References

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance
    1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–507. doi: 10.1038/nature12060. - DOI - PMC - PubMed
    1. Lindenbach B, Rice C. Flaviviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields’ Virology. 4. Lippincott Williams & Wilkins; 2001. pp. 991–1041.
    1. Vasilakis N, Cardosa J, Diallo M, et al. Sylvatic dengue viruses share the pathogenic potential of urban/endemic dengue viruses. J Virol. 2010;84(7):3726–3728. doi: 10.1128/JVI.02640-09. - DOI - PMC - PubMed
    1. Fagbami AH, Monath TP, Fabiyi A. Dengue virus infections in Nigeria: a survey for antibodies in monkeys and humans. Trans R Soc Trop Med Hyg. 1977;71(1):60–65. doi: 10.1016/0035-9203(77)90210-3. - DOI - PubMed
    1. Wang E, Ni H, Xu R, et al. Evolutionary Relationships of endemic/epidemic and sylvatic dengue viruses. J Virol. 2000;74(7):3227–3234. doi: 10.1128/JVI.74.7.3227-3234.2000. - DOI - PMC - PubMed

LinkOut - more resources